Catalyst
Slingshot members are tracking this event:
ANI Pharmaceuticals Announces FDA Approval of Oxcarbazepine Tablets
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ANIP | Community voting in process | |||||
Additional Information
Arthur S. Przybyl, ANI’s President and CEO stated, “This approval is the result of ANI’s ongoing effort to re-activate the discontinued ANDAs that we have acquired in recent years. The PAS included the successful qualification of a new API source for the drug substance as well as the addition of manufacturing and packaging at ANI’s Baudette site.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 13, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Oxcarbazepine
